Carvacrol Induces Doxorubicin-Resistant Breast Cancer Cell Apoptosis via Inhibition of the PI3K/Akt Pathway

Hu-Hu Chen and Jiao-han Zhou and Siat Yee Fong (2024) Carvacrol Induces Doxorubicin-Resistant Breast Cancer Cell Apoptosis via Inhibition of the PI3K/Akt Pathway. Pakistan Journal of Zoology, 56. pp. 1-8. ISSN 0030-9923

[img] Text
FULL TEXT.pdf
Restricted to Registered users only
Download (1MB) | Request a copy

Abstract

Doxorubicin (Dox), a widely used chemotherapeutic agent for breast cancer, is often ineffective due to the development of Dox resistance, posing a significant challenge in cancer treatment. Carvacrol is a monoterpene phenol with diverse biological activities, has emerged as a potential anticancer agent. However, its antitumor effects and underlying mechanism against Dox-resistant breast cancer remain largely unexplored. This study investigated the effect of carvacrol on cell viability, cell cycle progression, and apoptosis in Dox-resistant triple negative breast cancer (TNBC) MDA-MB-231/Dox cells. Western blotting analyses were performed to access protein levels associated with apoptosis and the PI3K/Akt pathway. The results revealed that carvacrol significantly inhibited MDA-MB-231/Dox cell proliferation in a concentration-dependent manner compared to the control (p <0.05). Furthermore, carvacrol treatment increased the distribution of MDA-MB-231/Dox cells in the G0 /G1 phase while decreasing the distribution in the S and G2 /M phases (p <0.05). Moreover, carvacrol treatment enhanced the apoptosis rate and Bax protein expression, while decreasing Bcl-2, PI3K and P-Akt protein levels, indicating that carvacrol treatment induced cell apoptosis by deactivating the PI3K/Akt signaling pathway. These findings suggest that carvacrol holds promise as a therapeutic strategy for Dox-resistant breast cancer, providing novel insights into the development of effective therapies that address drug resistance and improve patient outcomes

Item Type: Article
Keyword: Carvacrol, Breast cancer, Apoptosis, Dox-resistance, PI3K/Akt signaling pathway
Subjects: R Medicine > RC Internal medicine > RC31-1245 Internal medicine > RC254-282 Neoplasms. Tumors. Oncology Including cancer and carcinogens
R Medicine > RS Pharmacy and materia medica > RS153-441 Materia medica > RS400-431 Pharmaceutical chemistry
Department: FACULTY > Faculty of Medicine and Health Sciences
Depositing User: ABDULLAH BIN SABUDIN -
Date Deposited: 02 May 2025 10:52
Last Modified: 02 May 2025 10:52
URI: https://eprints.ums.edu.my/id/eprint/43688

Actions (login required)

View Item View Item